APO RESEARCH · REPORT
Oligonucleotide Therapeutics
Many pharmaceutical companies were conducting research on oligonucleotide therapy, which employs chemically synthesized nucleotide-like small molecule drugs with potential specificity similar to that of therapeutic antibodies.
Product & engineering
Understand the product.
Many pharmaceutical companies were conducting research on oligonucleotide therapy, which employs chemically synthesized nucleotide-like small molecule drugs with potential specificity similar to that of therapeutic antibodies.
Although several types of oligonucleotide therapies exist, five of them are compared here, including the ones targeting nucleic acids (such as mRNA) or proteins, as well as others intended for stimulation of the immune system. DDS is generally used with oligonucleotide therapy, as it is difficult for these molecules to penetrate cell membrane when administered on their own.
Selected research
Industry Research
Oligonucleotide Therapeutics Industry Research Report 2026
Market perspective
Many pharmaceutical companies were conducting research on oligonucleotide therapy, which employs chemically synthesized nucleotide-like small molecule drugs with potential specificity similar to that of therapeutic antibodies.
Although several types of oligonucleotide therapies exist, five of them are compared here, including the ones targeting nucleic acids (such as mRNA) or proteins, as well as others intended for stimulation of the immune system. DDS is generally used with oligonucleotide therapy, as it is difficult for these molecules to penetrate cell membrane when administered on their own.
Biogen is the industry's biggest player, with more than 76 percent of 2018 revenue, followed by Sarepta Therapeutics and Jazz Pharmaceuticals, with 13.35 percent and 6.63 percent, respectively. North America and Europe are the most important regions, accounting for more than 80 percent of the combined income.
Read the full market overview
Report Scope
This report quantifies the global Oligonucleotide Therapeutics market in terms of revenue (US$ million) and, where applicable, service volume (Unit), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/Unit) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Oligonucleotide Therapeutics.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Oligonucleotide Therapeutics Market by Company
Biogen
Sarepta Therapeutics
Jazz Pharmaceuticals
Bausch & Lomb
Alnylam Pharmaceuticals
Dynavax Technologies
Kastle therapeutics
Akcea Therapeutics
Oligonucleotide Therapeutics Segment by Type
Antisense Oligonucleotide
Aptamer
Other
Oligonucleotide Therapeutics Segment by Application
Neuromuscular Diseases
ATTR
Hepatic VOD
Other
Oligonucleotide Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oligonucleotide Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Oligonucleotide Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oligonucleotide Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Oligonucleotide Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Antisense Oligonucleotide
- Aptamer
- Other
Applications
- Neuromuscular Diseases
- ATTR
- Hepatic VOD
- Other
Companies covered
- Biogen
- Sarepta Therapeutics
- Jazz Pharmaceuticals
- Bausch & Lomb
- Alnylam Pharmaceuticals
- Dynavax Technologies
- Kastle therapeutics
- Akcea Therapeutics
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Oligonucleotide Therapeutics by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Antisense Oligonucleotide
- 2.2.3 Aptamer
- 2.2.4 Other
- 2.3 Oligonucleotide Therapeutics by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Neuromuscular Diseases
- 2.3.3 ATTR
- 2.3.4 Hepatic VOD
- 2.3.5 Other
- 2.4 Assumptions and Limitations
3 Oligonucleotide Therapeutics Breakdown Data by Type
- 3.1 Global Oligonucleotide Therapeutics Historic Market Size by Type (2021-2026)
- 3.2 Global Oligonucleotide Therapeutics Forecasted Market Size by Type (2027-2032)
4 Oligonucleotide Therapeutics Breakdown Data by Application
- 4.1 Global Oligonucleotide Therapeutics Historic Market Size by Application (2021-2026)
- 4.2 Global Oligonucleotide Therapeutics Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Oligonucleotide Therapeutics Market Perspective (2021-2032)
- 5.2 Global Oligonucleotide Therapeutics Growth Trends by Region
- 5.2.1 Global Oligonucleotide Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Oligonucleotide Therapeutics Historic Market Size by Region (2021-2026)
- 5.2.3 Oligonucleotide Therapeutics Forecasted Market Size by Region (2027-2032)
- 5.3 Oligonucleotide Therapeutics Market Dynamics
- 5.3.1 Oligonucleotide Therapeutics Industry Trends
- 5.3.2 Oligonucleotide Therapeutics Market Drivers
- 5.3.3 Oligonucleotide Therapeutics Market Challenges
- 5.3.4 Oligonucleotide Therapeutics Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Oligonucleotide Therapeutics Players by Revenue
- 6.1.1 Global Top Oligonucleotide Therapeutics Players by Revenue (2021-2026)
- 6.1.2 Global Oligonucleotide Therapeutics Revenue Market Share by Players (2021-2026)
- 6.2 Global Oligonucleotide Therapeutics Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Oligonucleotide Therapeutics Head Office and Area Served
- 6.4 Global Oligonucleotide Therapeutics Players, Product Type & Application
- 6.5 Global Oligonucleotide Therapeutics Manufacturers Established Date
- 6.6 Global Oligonucleotide Therapeutics Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Oligonucleotide Therapeutics Market Size (2021-2032)
- 7.2 North America Oligonucleotide Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Oligonucleotide Therapeutics Market Size by Country (2021-2026)
- 7.4 North America Oligonucleotide Therapeutics Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Oligonucleotide Therapeutics Market Size (2021-2032)
- 8.2 Europe Oligonucleotide Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Oligonucleotide Therapeutics Market Size by Country (2021-2026)
- 8.4 Europe Oligonucleotide Therapeutics Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Oligonucleotide Therapeutics Market Size (2021-2032)
- 9.2 Asia-Pacific Oligonucleotide Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Oligonucleotide Therapeutics Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Oligonucleotide Therapeutics Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Oligonucleotide Therapeutics Market Size (2021-2032)
- 10.2 South America Oligonucleotide Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Oligonucleotide Therapeutics Market Size by Country (2021-2026)
- 10.4 South America Oligonucleotide Therapeutics Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Oligonucleotide Therapeutics Market Size (2021-2032)
- 11.2 Middle East & Africa Oligonucleotide Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Oligonucleotide Therapeutics Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Oligonucleotide Therapeutics Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Biogen
- 12.1.1 Biogen Company Information
- 12.1.2 Biogen Business Overview
- 12.1.3 Biogen Revenue in Oligonucleotide Therapeutics Business (2021-2026)
- 12.1.4 Biogen Oligonucleotide Therapeutics Product Portfolio
- 12.1.5 Biogen Recent Developments
- 12.2 Sarepta Therapeutics
- 12.2.1 Sarepta Therapeutics Company Information
- 12.2.2 Sarepta Therapeutics Business Overview
- 12.2.3 Sarepta Therapeutics Revenue in Oligonucleotide Therapeutics Business (2021-2026)
- 12.2.4 Sarepta Therapeutics Oligonucleotide Therapeutics Product Portfolio
- 12.2.5 Sarepta Therapeutics Recent Developments
- 12.3 Jazz Pharmaceuticals
- 12.3.1 Jazz Pharmaceuticals Company Information
- 12.3.2 Jazz Pharmaceuticals Business Overview
- 12.3.3 Jazz Pharmaceuticals Revenue in Oligonucleotide Therapeutics Business (2021-2026)
- 12.3.4 Jazz Pharmaceuticals Oligonucleotide Therapeutics Product Portfolio
- 12.3.5 Jazz Pharmaceuticals Recent Developments
- 12.4 Bausch & Lomb
- 12.4.1 Bausch & Lomb Company Information
- 12.4.2 Bausch & Lomb Business Overview
- 12.4.3 Bausch & Lomb Revenue in Oligonucleotide Therapeutics Business (2021-2026)
- 12.4.4 Bausch & Lomb Oligonucleotide Therapeutics Product Portfolio
- 12.4.5 Bausch & Lomb Recent Developments
- 12.5 Alnylam Pharmaceuticals
- 12.5.1 Alnylam Pharmaceuticals Company Information
- 12.5.2 Alnylam Pharmaceuticals Business Overview
- 12.5.3 Alnylam Pharmaceuticals Revenue in Oligonucleotide Therapeutics Business (2021-2026)
- 12.5.4 Alnylam Pharmaceuticals Oligonucleotide Therapeutics Product Portfolio
- 12.5.5 Alnylam Pharmaceuticals Recent Developments
- 12.6 Dynavax Technologies
- 12.6.1 Dynavax Technologies Company Information
- 12.6.2 Dynavax Technologies Business Overview
- 12.6.3 Dynavax Technologies Revenue in Oligonucleotide Therapeutics Business (2021-2026)
- 12.6.4 Dynavax Technologies Oligonucleotide Therapeutics Product Portfolio
- 12.6.5 Dynavax Technologies Recent Developments
- 12.7 Kastle therapeutics
- 12.7.1 Kastle therapeutics Company Information
- 12.7.2 Kastle therapeutics Business Overview
- 12.7.3 Kastle therapeutics Revenue in Oligonucleotide Therapeutics Business (2021-2026)
- 12.7.4 Kastle therapeutics Oligonucleotide Therapeutics Product Portfolio
- 12.7.5 Kastle therapeutics Recent Developments
- 12.8 Akcea Therapeutics
- 12.8.1 Akcea Therapeutics Company Information
- 12.8.2 Akcea Therapeutics Business Overview
- 12.8.3 Akcea Therapeutics Revenue in Oligonucleotide Therapeutics Business (2021-2026)
- 12.8.4 Akcea Therapeutics Oligonucleotide Therapeutics Product Portfolio
- 12.8.5 Akcea Therapeutics Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst